317 related articles for article (PubMed ID: 36717630)
1. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.
Mori K; Tanaka M; Hosaka I; Mikami T; Endo K; Hanawa N; Ohnishi H; Furuhashi M
Hypertens Res; 2023 May; 46(5):1110-1121. PubMed ID: 36717630
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
5. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
Theofilis P; Vordoni A; Tsimihodimos V; Kalaitzidis RG
High Blood Press Cardiovasc Prev; 2023 Jan; 30(1):63-72. PubMed ID: 36626077
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
11. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
[TBL] [Abstract][Full Text] [Related]
13. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
14. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
15. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.
Imai J; Takashimizu S; Suzuki N; Ohshinden K; Sawamoto K; Mishima Y; Tsuruya K; Arase Y; Yamano M; Kishimoto N; Yamada C; Inoue N; Moriyama K; Baba A; Suzuki H; Kagawa T; Nishizaki Y
Sci Rep; 2024 Jun; 14(1):13411. PubMed ID: 38862756
[TBL] [Abstract][Full Text] [Related]
17. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals.
Tanaka M; Takahashi S; Higashiura Y; Sakai A; Koyama M; Saitoh S; Shimamoto K; Ohnishi H; Furuhashi M
J Diabetes Investig; 2022 May; 13(5):878-888. PubMed ID: 34889064
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016.
Zhang HJ; Wang YY; Chen C; Lu YL; Wang NJ
Chin Med J (Engl); 2021 Jun; 134(13):1593-1601. PubMed ID: 34091530
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome.
Liu CC; Huang SP; Lee YC; Lee CH; Huang TY; Geng JH; Chang CW; Lin CY; Juan YS; Wu WJ; Hsieh TJ
Front Endocrinol (Lausanne); 2023; 14():1252774. PubMed ID: 37854195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
